Metagenomi to Participate in Upcoming Investor Conferences
Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced its participation in two upcoming investor conferences. The company will present at the Wells Fargo Healthcare Conference on September 4, 2024, and the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024.
Key executives, including CEO Brian Thomas, CMO Dr. Sarah Noonberg, SVP Preclinical Alan Brooks, and CFO Pamela Wapnick, will represent Metagenomi at these events. The presentations will be available via live webcast on the company's investor relations website, with replays accessible for a time.
Metagenomi specializes in developing curative therapeutics using its proprietary, metagenomics-derived toolbox. The company's comprehensive genome editing toolkit includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, positioning Metagenomi to address a wide range of genetic mutations.
Metagenomi (Nasdaq: MGX), un'azienda di medicine genetiche di precisione, ha annunciato la sua partecipazione a due prossime conferenze per investitori. L'azienda si presenterà alla Wells Fargo Healthcare Conference il 4 settembre 2024 e al H.C. Wainwright 26th Annual Global Investment Conference il 9 settembre 2024.
Alcuni dirigenti chiave, tra cui il CEO Brian Thomas, il CMO Dr. Sarah Noonberg, il SVP Preclinico Alan Brooks e la CFO Pamela Wapnick, rappresenteranno Metagenomi in questi eventi. Le presentazioni saranno disponibili tramite webcast in diretta sul sito web delle relazioni con gli investitori dell'azienda, con le registrazioni accessibili per un periodo di tempo.
Metagenomi si specializza nello sviluppo di terapie curative utilizzando il suo esclusivo toolbox derivato dalla metagenomica. L'ampio kit di strumenti per l'editing del genoma dell'azienda include nucleasi programmabili, editor di basi e sistemi di integrazione mediati da RNA e DNA, posizionando Metagenomi per affrontare un'ampia gamma di mutazioni genetiche.
Metagenomi (Nasdaq: MGX), una empresa de medicamentos genéticos de precisión, ha anunciado su participación en dos próximas conferencias para inversores. La empresa se presentará en la Wells Fargo Healthcare Conference el 4 de septiembre de 2024 y en la H.C. Wainwright 26th Annual Global Investment Conference el 9 de septiembre de 2024.
Ejecutivos clave, incluyendo al CEO Brian Thomas, la CMO Dra. Sarah Noonberg, el SVP Preclínico Alan Brooks y la CFO Pamela Wapnick, representarán a Metagenomi en estos eventos. Las presentaciones estarán disponibles a través de un webcast en vivo en el sitio web de relaciones con inversores de la empresa, con repeticiones accesibles durante un tiempo limitado.
Metagenomi se especializa en el desarrollo de terapias curativas utilizando su caja de herramientas derivada de metagenómica. El completo kit de edición del genoma de la empresa incluye nucleasas programables, editores de bases y sistemas de integración mediados por ARN y ADN, posicionando a Metagenomi para abordar un amplio rango de mutaciones genéticas.
메타게노미(Metagonomi) (Nasdaq: MGX)는 정밀 유전 의약품 회사로, 두 가지 다가오는 투자자 회의에 참여할 것이라고 발표했습니다. 회사는 2024년 9월 4일 웰스 파고 헬스케어 회의와 2024년 9월 9일 H.C. 웨인라이트 제26회 연례 글로벌 투자 회의에서 발표할 것입니다.
CEO 브라이언 토마스, CMO Dr. 사라 누웬버그, SVP 전임상 앨런 브룩스, CFO 파멜라 와프닉 등 주요 경영진들이 이 행사에서 메타게노미를 대표할 것입니다. 프레젠테이션은 회사의 투자자 관계 웹사이트에서 실시간으로 웹캐스트로 제공되며, 재생은 일정 기간 동안 접근할 수 있습니다.
메타게노미는 자사의 독점 메타게놈으로 파생된 도구 상자를 활용하여 치유 치료제를 개발하는 전문 회사입니다. 회사의 포괄적인 유전체 편집 도구 키트에는 프로그래머블 뉴클레아제, 기초 편집기 및 RNA와 DNA 매개 통합 시스템이 포함되어 있어, 메타게노미는 다양한 유전적 돌연변이에 효과적으로 대응할 수 있는 위치에 있습니다.
Metagenomi (Nasdaq: MGX), une entreprise spécialisée dans les médicaments génétiques de précision, a annoncé sa participation à deux prochaines conférences pour investisseurs. L'entreprise fera une présentation lors de la Wells Fargo Healthcare Conference le 4 septembre 2024, et lors de la H.C. Wainwright 26e Conférence Annuelle Mondiale d'Investissement le 9 septembre 2024.
Des cadres clés, y compris le PDG Brian Thomas, la CMO Dr. Sarah Noonberg, le SVP Préclinique Alan Brooks et la CFO Pamela Wapnick, représenteront Metagenomi lors de ces événements. Les présentations seront disponibles via un webinaire en direct sur le site Web des relations investisseurs de l'entreprise, avec des rediffusions accessibles pendant une période donnée.
Metagenomi se spécialise dans le développement de thérapies curatives en utilisant son outil exclusif dérivé de la métagénomique. La boîte à outils complète de l'édition du génome de l'entreprise comprend des nucléases programmables, des éditeurs de base et des systèmes d'intégration médiés par l'ARN et l'ADN, positionnant Metagenomi pour aborder une large gamme de mutations génétiques.
Metagenomi (Nasdaq: MGX), ein Unternehmen für präzise genetische Medizin, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird am Wells Fargo Healthcare Conference am 4. September 2024 und am H.C. Wainwright 26. jährliche globale Investorenkonferenz am 9. September 2024 teilnehmen.
Wichtige Führungskräfte, darunter CEO Brian Thomas, CMO Dr. Sarah Noonberg, SVP für präklinische Forschung Alan Brooks und CFO Pamela Wapnick, werden Metagenomi bei diesen Veranstaltungen vertreten. Die Präsentationen werden über einen Live-Stream auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit Aufzeichnungen, die eine Zeit lang zugänglich sind.
Metagenomi spezialisiert sich auf die Entwicklung heilender Therapeutika mit Hilfe seines proprietären, aus Metagenomik abgeleiteten Werkzeugs. Das umfassende Werkzeugset zur Genom-Editierung des Unternehmens umfasst programmierbare Nukleasen, Basiseditoren und RNA- sowie DNA-vermittelte Integrationssysteme, was Metagenomi in die Lage versetzt, ein breites Spektrum von genetischen Mutationen anzusprechen.
- None.
- None.
EMERYVILLE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that it will present during the following upcoming investor conferences:
Wells Fargo Healthcare Conference, Everett, Massachusetts
Fireside chat on Wednesday, September 4, 2024, 11:00 AM - 11:35 AM ET with Brian Thomas, CEO, Dr. Sarah Noonberg, CMO, and Alan Brooks, SVP Preclinical
H.C. Wainwright 26th Annual Global Investment Conference, New York City
Corporate presentation on Monday, September 9, 2024, 11:30 AM - 12:00 PM ET with Dr. Sarah Noonberg, CMO, and Pamela Wapnick, CFO
The live conference webcasts will be available in the investor section of the company's website at https://ir.metagenomi.co/. A replay will be available for a limited time at the same address.
About Metagenomi
Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat associated transposases). Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. For more information, please visit https://metagenomi.co.
Cautionary Note Regarding Forward‐Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to conduct IND-enabling studies, make regulatory filings such as INDs, statements concerning the potential of therapies and product candidates, statements concerning the timing of data presentations and publications, and any other statements that are not historical facts. Forward looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in “Risk Factors,” in our most recent Form 10-K and our most recent 10-Qs on file with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Investor Contact:
Simon Harnest - CIO, SVP Investor Relations
simon@metagenomi.co
Media Contact:
Ashlye Hodge - Communications Manager
ashlye@metagenomi.co
FAQ
When and where will Metagenomi (MGX) present at the Wells Fargo Healthcare Conference?
Who will represent Metagenomi (MGX) at the H.C. Wainwright Global Investment Conference?
How can investors access Metagenomi's (MGX) conference presentations?
What is Metagenomi's (MGX) main focus in genetic medicine?
